Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

10 Jul 2008 07:00

RNS Number : 7470Y
Angle PLC
10 July 2008
 



For Immediate Release

10 July 2008

ANGLE plc

ANGLE Long-term Management Contract Win

Contract Value Increased by £1.7m to £5.4m

ANGLE plc ('ANGLE' or the 'Company'), the intellectual property and technology commercialisation company, is pleased to announce that following confirmation of preferred bidder status in February 2008, it has now been awarded the long term management contract of the London Development Agency's (LDA) Knowledge Connect Programme. 

In addition, it was originally announced that the value of this contract to ANGLE would be £3.7 million over three years. However, as a result of the LDA’s success in principle in securing European ERDF funds to support the programme, ANGLE is today pleased to announce that, subject to contract finalisation, the value of the Programme will be increased by £1.7 million to £5.4 million, once again over the next three years.

The Knowledge Connect Programme aims to increase the level of business research and development in London by creating new collaborations between business and the London knowledge base, with a focus on enterprises that have not previously worked with this sector.
 
This flagship Programme, a core part of the LDA’s Knowledge Transfer Strategy, will engage with a minimum of 2,880 businesses and involve ANGLE working intensively with more than 470 businesses across London. The Programme is being established to raise the performance and aspirations of London’s businesses by providing effective support for research and development, knowledge transfer and innovation across the Capital.
 
ANGLE was selected following a competitive tendering process on the basis of its experience in delivering similar business support programmes in London, UK wide and internationally. Additionally ANGLE has developed techniques which it was able to demonstrate have secured successful knowledge transfer from academic and research institutions across the World and that have measurable business benefits for a wide range of small and medium sized enterprises (SMEs).

Andrew Newland, Chief Executive of ANGLE, said:

"ANGLE's Management services business is a key feature of the Company's business model. The division provides top line revenue, is profitable and cash generative. However, it also provides the Company with access to leading academic, research and science organisations internationally, raising the profile of the whole Group and providing access to high quality IP commercialisation opportunities.

The award of this contract is not only a further success for our Management services business, but also underlines our strategy of focusing on long-term contracts that have the potential to generate significant revenues and earnings for the Group. We are delighted to be working on this project with not only the London Development Agency, but also more broadly with London's business and research communities to help identify new opportunities and secure business growth through knowledge transfer and innovation.”

Garth Selvey, Chairman of ANGLE, added: 

"This project adds to the strength of our Management services business, which provides the platform for the creation of real value in ANGLE's Progeny operation.

The Board believes that in the last five years ANGLE has generated significant inherent value in its underlying portfolio of companies, several of which are now at a stage of development to potentially deliver substantial cash returns for shareholders."

Enquiries:

ANGLE plc

01483 295830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Mark Connelly, Stewart Wallace

 

0207 523 8350

Scott Harris 

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

Buchanan Communications

Suzanne Brocks, James Strong

 

0207 466 5000

Notes to Editors

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

ANGLE is an active investor in high growth companies in the medical and technology sectors in both the UK and the US, taking operational responsibility for the companies as subsidiaries during the development phase and maintaining a substantial shareholding and close involvement during the growth phase. ANGLE has significant holdings in 10 portfolio companies developing proven technologies targeting substantial commercial markets. ANGLE is listed on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUKAORWRRBRUR
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.